greeksoup/ stock research
Stock research / United States / BNTX / Year to 31 December 2017

BioNTech SE (BNTX) annual results, year to 31 December 2017: revenue EUR 61.6 million, from the 20-F

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2017 it reported revenue of EUR 61.6 million ($70 million at the year's average rate). Its profit attributable to shareholders was EUR -85.7 million.

Revenue
EUR 61.6 million
FY2017FY2017
Operating margin
-99.5%
FY2017FY2017
Net income
EUR -85.7 million
FY2017FY2017
Diluted EPS
n/a
FY2017FY2017

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2017
Revenue61.6
Cost of sales9.3
Gross profit52.3
Research and development85.5
Operating profit-61.3
Finance costs26.0
Profit before tax-85.9
Income tax0.0
Profit for the year-86.0
Profit attributable to shareholders-85.7
Filing20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.

Cash flow

Year toDec 2017
Cash from operations-52.6
Purchase of property, plant and equipment24.3
Free cash flow-76.9
Cash from investing-52.5
Cash from financing-1.6
Depreciation and amortisation10.5
Filing20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2017
Funded by
Equity attributable to shareholders-48.2
Owned
Property, plant and equipment49.6
Cash and cash equivalents172
Filing20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2017
Gross margin84.9%
Operating margin-99.5%
Net margin-139.1%
Free cash flow margin-124.8%
Filing20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2017, filed 31 March 2020: the filing. The figures are in euros as filed.